Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | SIRT2 | Q8IXJ6 | 3/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.36 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2507036 | 1.00 | TSHR (0.42) | TSHRNPSR1RXFP1KMT2AMAPK1 | |
| Hydrochloric Acid SCHEMBL30943478 | 0.99 | TSHR (0.41) | TSHRNPSR1RXFP1KMT2AMAPK1 | |
| Phosphine SCHEMBL28247442 | 0.99 | TSHR (0.41) | TSHRNPSR1RXFP1KMT2AMAPK1 | |
| SCHEMBL27808614 | 0.99 | TSHR (0.41) | TSHRNPSR1RXFP1KMT2AMAPK1 | |
| SCHEMBL29360593 | 0.94 | TSHR (0.46) | TSHRNPSR1RXFP1KMT2AMAPK1 | |
| Fluoride Ion SCHEMBL17601912 | 0.93 | TSHR (0.45) | TSHRNPSR1RXFP1KMT2AMAPK1 | |
| SCHEMBL28555388 | 0.91 | TSHR (0.36) | TSHRNPSR1RXFP1KMT2AMAPK1 | |
| SCHEMBL8623356 | 0.90 | TSHR (0.41) | TSHRNPSR1RXFP1KMT2AMAPK1 | |
| Benzotriazole SCHEMBL23699039 | 0.89 | TSHR (0.35) | TSHRNPSR1RXFP1KMT2AMAPK1 | |
| SCHEMBL3679296 | 0.89 | TSHR (0.40) | TSHRNPSR1RXFP1KMT2AMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 956 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4712957-A2 | ISOANDROGRAPHOLIDE ANALOGS AND METHOD FOR TREATMENT USING THE SAME | Enveda Therapeutics, Inc. (US) | 2026-03-25 | — | — | EP | claimed |
| US-20260014184-A1 | ADENOSINE DERIVATIVES FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISORDERS AND CANCER | UNIV COLLEGE CARDIFF CONSULTANTS LTD (GB) | 2026-01-15 | — | — | US | claimed |
| EP-4673426-A1 | FUNCTIONALIZED BIODEGRADABLE SURFACTANTS AND METHODS USE | Locus Solutions IPCO, LLC (US) | 2026-01-07 | — | — | EP | claimed |
| EP-4662222-A1 | PROCESS FOR THE PREPARATION OF TETRAPEPTIDE FRAGMENT OF LIRAGLUTIDE | Fresenius Kabi Oncology Ltd (IN) | 2025-12-17 | — | — | EP | claimed |
| EP-4658396-A1 | BELT REACTOR MANUFACTURING PROCESS FOR OLIGOMER SYNTHESIS | Arrowhead Pharmaceuticals, Inc. (US) | 2025-12-10 | — | — | EP | claimed |
| EP-4622991-A2 | SYNTHESIS OF A CYCLIC PEPTIDE | Janssen Pharmaceutica NV (BE) | 2025-10-01 | — | — | EP | claimed |
| EP-4619408-A1 | THE SYNTHESIS OF OMAPATRILAT | Endothelium Scanning Nanotechnology Limited (AU) | 2025-09-24 | — | — | EP | claimed |
| WO-2025149985-A1 | METHODS OF PREPARING MELANOCORTIN 4 RECEPTOR AGONISTS | LG CHEM, LTD. (KR) | 2025-07-17 | — | — | WO | claimed |
| WO-2025122535-A2 | LIQUID PHASE PEPTIDE SYNTHESIS METHODS | AMGEN INC. (US) | 2025-06-12 | — | — | WO | claimed |
| EP-4565709-A1 | CATIONIC SURFACTANTS WITH IMPROVED PH STABILITY AND THEIR USE | Locus Solutions IPCO, LLC (US) | 2025-06-11 | — | — | EP | claimed |
| WO-2022174190-A1 | ENHANCED SOPHOROLIPID DERIVATIVES | LOCUS IP COMPANY, LLC (US) | 2022-08-18 | — | — | WO | claimed |
| WO-2022171683-A1 | BIOACTIVE COMPOUND IMMOBILIZATION ON SULFONE POLYMERS | SOLVAY SPECIALTY POLYMERS USA, LLC (US) | 2022-08-18 | — | — | WO | claimed |
| WO-2022162447-A1 | PROCESSES FOR PREPARATION OF CHLORANTRANILIPROLE OR A SALT OR ITS INTERMEDIATES THEREOF | LAURUS LABS LIMITED (IN) | 2022-08-04 | — | — | WO | claimed |
| CN-114805308-A | Method for synthesizing aminopyrimidine FAK inhibitor compound | 海创药业股份有限公司 | 2022-07-29 | — | — | CN | claimed |
| CN-114773352-A | Process for preparing substituted nicotinamides | 上海赛默罗生物科技有限公司 | 2022-07-22 | — | — | CN | claimed |
| WO-2022152315-A1 | SYNTHESIS METHOD FOR AMINOPYRIMIDINE FAK INHIBITOR COMPOUND | 海创药业股份有限公司 | 2022-07-21 | — | — | WO | claimed |
| EP-4013382-A1 | FILM FORMULATION COMPRISING CARRIERS | Klaria Pharma Holding AB (SE) | 2022-06-22 | — | — | EP | claimed |
| EP-3986919-A1 | PROCESS FOR THE MANUFACTURE OF GLUCAGON | Fresenius Kabi iPSUM S.r.l. (IT) | 2022-04-27 | — | — | EP | claimed |
| EP-3986400-A1 | PROCESSES AND INTERMEDIATES FOR PRODUCING DIAZASPIRO LACTAM COMPOUNDS | Naurex Inc. (US) | 2022-04-27 | — | — | EP | claimed |
| EP-3972627-A1 | METHODS FOR PREPARING PSMA CONJUGATES | Endocyte, Inc. (US) | 2022-03-30 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260014184-A1 | ADENOSINE DERIVATIVES FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISORDERS AND CANCER | ADRM1, ADORA1, ADORA2A | TSHR 3012/4885NPSR1 2219/4885RXFP1 3529/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.